ArticleScience advances2019
Genetic and structural insights into broad neutralization of hepatitis C virus by human V
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 97 citations in OpenAlex.
- Article
- Structure-based design of stable recombinant hepatitis C virus E1E2 heterodimers.Nature communications · 2026Article
- Immune Factors Linked to Long-Term HCV Humoral Memory Five Years After Cure in People with HIV: A Cross-Sectional Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2.NPJ vaccines · 2026Article
- Immunogenicity assessment and epitope mapping of the ASFV proteome by profiling serum antibodies with ASFV antigen phage libraries.Communications biology · 2026Article
- Native-like soluble E1E2 glycoprotein heterodimers on self-assembling protein nanoparticles for hepatitis C virus vaccine design.Nature communications · 2026Article
- Targets of protective immunity and opportunities in hepatitis C virus vaccine development.Nature reviews. Immunology · 2026Review
- mAbClust with AlphaFold 3 avoids hallucinations to define a quaternary broadly neutralizing HCV epitope.bioRxiv : the preprint server for biology · 2026Article
- Recurrent antibody repertoire features associated with six selected human IGHV genes: V(D)J usage, heavy-light pairing, and CDRH3 properties.Frontiers in immunology · 2026Article
- Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.Frontiers in immunology · 2026Review
- Explore antibody repertoire in the era of AI.Acta biochimica et biophysica Sinica · 2025Article
- Broadly Neutralizing Antibody Characteristics in Hepatitis C Virus Infection and Implications for Vaccine Design.Vaccines · 2025Review
- Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers.Communications biology · 2025Article
- Review
- Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies.PLoS pathogens · 2025Article
- Article
- Article
- Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development.Viruses · 2024Review
- Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance.Immunity · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Netanel TzarumDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Erick GiangDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Leopold KongDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Linling HeDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-8846-5352
Jannick PrentoeCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2203-9478
Elias AugestadCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0917-3971
Yuanzi HuaDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Shaun CastilloDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7478-3077
Georg M LauerGastrointestinal Unit and Liver Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-9792-4271
Jens BukhCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Hvidovre Hospital, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7815-4806
Jiang ZhuDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-0259-7157
Ian A WilsonDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6469-2419
Mansun LawDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8934-9756
Scripps Research Institute · USUniversity of Copenhagen · DKMassachusetts General Hospital · US
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI GODZIK, ADAM · 2012 to 2018
$131.5MZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI SCOTT, EMILY E · 1985 to 2011
$38.9MX-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MScripps Translational Science InstituteUL1TR001114 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2013 to 2017
$24.0MPushing the envelope: Optimizing vaccine display of flexibly linked HIV Env trimer immunogensP01AI124337 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI ZHU, JIANG · 2016 to 2020
$12.2MUnderstanding human neutralizing antibodies to hepatitis C virusR01AI079031 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2008 to 2017
$4.6MNovel HCV vaccine antigens targeting conserved neutralizing epitopesU19AI123861 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2016 to 2020
$4.6MRational design and B cell responses of HIV epitope vaccinesR01AI129698 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHU, JIANG · 2017 to 2021
$3.2MStructure and function of Hepacivirus envelope glycoproteinR01AI123365 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN, WILSON, IAN A · 2016 to 2020
$3.1MDissecting virus neutralizing determinants to guide HCV vaccine developmentR01AI106005 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAW, MANSUN · 2014 to 2017
$1.5MImmune Control and Evadion during Acute HCV InfectionU01AI131314 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2016 to 2020
$1.4MNCATS NIH HHS UL1 TR001114NCRR NIH HHS P41 RR001209NIAID NIH HHS P01 AI124337NIAID NIH HHS R01 AI079031NIAID NIH HHS R01 AI106005NIAID NIH HHS R01 AI123365NIAID NIH HHS R01 AI129698NIAID NIH HHS U01 AI131314NIAID NIH HHS U19 AI123861NIGMS NIH HHS P41 GM103393
Abstract
An effective vaccine to the antigenically diverse hepatitis C virus (HCV) must target conserved immune epitopes. Here, we investigate cross-neutralization of HCV genotypes by broadly neutralizing antibodies (bNAbs) encoded by the relatively abundant human gene family
Indexed as
Antibodies, MonoclonalAntibodies, NeutralizingAntibody AffinityBinding SitesBlood DonorsCell Line, TumorCross ReactionsDual-Specificity PhosphatasesEpitopesHepacivirusHepatitis CHepatitis C AntibodiesHumansViral Envelope ProteinsViral Hepatitis VaccinesAntibodies, MonoclonalAntibodies, Neutralizingdual specificity phosphatase 12Dual-Specificity PhosphatasesEpitopesglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesViral Envelope ProteinsViral Hepatitis Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.